Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 6, 2010, Pages 641-652

  Le Quintrec, Moglie ^a   Roumenina, Lubka ^b   Noris, Marina ^c   Frémeaux Bacchi, Véronique ^b,d  

^a FOCH HOSPITAL   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

C3; CFH; CFI; factor B; MCP; thrombomodulin and thrombotic microangiopathy

Indexed keywords

COMPLEMENT; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; MEMBRANE COFACTOR PROTEIN; THROMBOMODULIN;

CLINICAL FEATURE; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEMOLYTIC UREMIC SYNDROME; HUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; REGULATOR GENE; REVIEW;

ANTIGENS, CD46; COMPLEMENT FACTOR H; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MUTATION; PENETRANCE;

EID: 77957577058     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1262886     Document Type: Review

References (57)

1. Sadler J E. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008 112 (1) 11-18
2. Moake J L. Thrombotic microangiopathies. N Engl J Med 2002 347 (8) 589-600
3. Tarr P I., Gordon C A., Chandler W L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005 365 (9464) 1073-1086
4. Copelovitch L, Kaplan B S. Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol 2008 23 (11) 1951-1956
5. Copelovitch L, Kaplan B S. The thrombotic microangiopathies. Pediatr Nephrol 2008 23 (10) 1761-1767
6. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009 361 (17) 1676-1687
7. Walport M J. Complement. First of two parts. N Engl J Med 2001 344 (14) 1058-1066
8. Zipfel P F., Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009 9 (10) 729-740
9. Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009 361 (4) 345-357
10. Pangburn M K. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J Immunol 2002 169 (9) 4702-4706
11. Jokiranta T S., Jaakola V P., Lehtinen M J., Prepalo M, Meri S, Goldman A. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J 2006 25 (8) 1784-1794
12. Wu J, Wu Y Q., Ricklin D, Janssen B J., Lambris J D., Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol 2009 10 (7) 728-733
13. Heinen S, Hartmann A, Lauer N et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009 114 (12) 2439-2447
14. Józsi M, Zipfel P F. Factor H family proteins and human diseases. Trends Immunol 2008 29 (8) 380-387
15. Liszewski M K., Kemper C, Price J D., Atkinson J P. Emerging roles and new functions of CD46. Springer Semin Immunopathol 2005 27 (3) 345-358
16. Nilsson S C., Nita I, Mánsson L et al. Analysis of binding sites on complement factor I that are required for its activity. J Biol Chem 2010 285 (9) 6235-6245
17. Cameron J S., Vick R. Letter: Plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet 1973 2 (7835) 975
18. Thompson R A., Winterborn M H. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 1981 46 (1) 110-119
19. Saunders R E., Abarrategui-Garrido C, Frémeaux-Bacchi V et al. The interactive factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and factor I mutations with structural models. Hum Mutat 2007 28 (3) 222-234
20. Pickering M C., Cook H T. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008 151 (2) 210-230
21. Rougier N, Kazatchkine M D., Rougier J P. et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998 9 (12) 2318-2326
22. Warwicker P, Goodship T H., Donne R L. et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998 53 (4) 836-844
23. Caprioli J, Bettinaglio P, Zipfel P F. et al, Itaslian Registry of Familial and Recurrent HUS/TTP. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001 12 (2) 297-307
24. Ferreira V P., Herbert A P., Cortés C et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009 182 (11) 7009-7018
25. Venables J P., Strain L, Routledge D et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006 3 (10) e431
26. Dragon-Durey M A., Loirat C, Cloarec S et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005 16 (2) 555-563
27. Józsi M, Strobel S, Dahse H M. et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007 110 (5) 1516-1518
28. Moore I, Strain L, Pappworth I et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4 and with mutations in CFH, CFI, CD46, and C3 in patients with atypical haemolytic uraemic syndrome. Blood 2010 115 (2) 379-387
29. Richards A, Kemp E J., Liszewski M K. et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003 100 (22) 12966-12971
30. Noris M, Brioschi S, Caprioli J et al, International Registry of Recurrent and Familial HUS/TTP. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003 362 (9395) 1542-1547
31. Freméaux-Bacchi V, Dragon-Durey M A., Blouin J et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004 41 (6) e84
32. Bienaimé F, Dragon-Durey M A., Regnier C H. et al. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010 77 (4) 339-349
33. Frémeaux-Bacchi V, Moulton E A., Kavanagh D et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006 17 (7) 2017-2025
34. Nilsson S C., Kalchishkova N, Trouw L A., Frémeaux-Bacchi V, Villoutreix B O., Blom A M. Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol 2010 40 (1) 172-185
35. Fang C J., Frémeaux-Bacchi V, Liszewski M K. et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008 111 (2) 624-632
36. Goicoechea de Jorge E, Harris C L., Esparza-Gordillo J et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007 104 (1) 240-245
37. Roumenina L T., Jablonski M, Hue C et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009 114 (13) 2837-2845
38. Frémeaux-Bacchi V, Miller E C., Liszewski M K. et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008 112 (13) 4948-4952
39. Furie B, Furie B C. Mechanisms of thrombus formation. N Engl J Med 2008 359 (9) 938-949
40. Stáhl A L., Vaziri-Sani F, Heinen S et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008 111 (11) 5307-5315
41. Licht C, Pluthero F G., Li L et al. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood 2009 114 (20) 4538-4545
42. Pickering M C., de Jorge E G., Martinez-Barricarte R et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007 204 (6) 1249-1256
43. Caprioli J, Noris M, Brioschi S et al, International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006 108 (4) 1267-1279
44. Dragon-Durey M A., Blanc C, Marliot F et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009 46 (7) 447-450
45. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005 14 (5) 703-712
46. Sullivan M, Erlic Z, Hoffmann M M. et al. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet 2010 74 (1) 17-26
47. Esparza-Gordillo J, Jorge E G., Garrido C A. et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 2006 43 (11) 1769-1775
48. Frémeaux-Bacchi V, Kemp E J., Goodship J A. et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet 2005 42 852-856
49. Martnez-Barricarte R, Goicoechea de Jorge E, Montes T, Layana A G., Rodrguez de Córdoba S. Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population. Clin Exp Immunol 2009 155 (1) 59-64
50. Blom A M., Bergström F, Edey M et al. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol 2008 180 (9) 6385-6391
51. Zipfel P F., Edey M, Heinen S et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007 3 (3) e41
52. Abarrategui-Garrido C, Martnez-Barricarte R, López-Trascasa M, de Córdoba S R., Snchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009 114 (19) 4261-4271
53. Sellier-Leclerc A L., Frémeaux-Bacchi V, Dragon-Durey M A. et al, French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007 18 (8) 2392-2400
54. Neumann H P., Salzmann M, Bohnert-Iwan B et al. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 2003 40 (9) 676-681
55. Dragon-Durey M A., Frémeaux-Bacchi V, Loirat C et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004 15 (3) 787-795
56. Geelen J, van den Dries K, Roos A et al. A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome. Pediatr Nephrol 2007 22 (3) 371-375
57. Kavanagh D, Kemp E J., Mayland E et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005 16 (7) 2150-2155